{"id":88793,"date":"2024-07-15T09:36:00","date_gmt":"2024-07-15T07:36:00","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=88793"},"modified":"2024-07-15T09:42:46","modified_gmt":"2024-07-15T07:42:46","slug":"andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/","title":{"rendered":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca"},"content":{"rendered":"<p><span class=\"normaltextrun\"><span lang=\"EN-US\">Andera Partners, a leading European private <\/span><\/span><span class=\"normaltextrun\"><span lang=\"EN-GB\">equity player, announced today that its portfolio company <\/span><\/span><span lang=\"EN-US\">Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company AstraZeneca.<\/span><\/p>\n<p><span lang=\"EN-US\">The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease. This programme, together with Amolyt\u2019s talented team, expertise, and earlier pipeline, will enable Alexion\u2019s expansion into rare endocrinology.\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\">Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma\u2019s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma\u2019s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.<\/span><span lang=\"EN-GB\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners, a leading European private equity player, announced today that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company AstraZeneca. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-88793","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners, a leading European private equity player, announced today that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company AstraZeneca. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-15T07:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-15T07:42:46+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca\",\"datePublished\":\"2024-07-15T07:36:00+00:00\",\"dateModified\":\"2024-07-15T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\"},\"wordCount\":211,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\",\"name\":\"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2024-07-15T07:36:00+00:00\",\"dateModified\":\"2024-07-15T07:42:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS","og_description":"Andera Partners, a leading European private equity player, announced today that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company AstraZeneca. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2024-07-15T07:36:00+00:00","article_modified_time":"2024-07-15T07:42:46+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca","datePublished":"2024-07-15T07:36:00+00:00","dateModified":"2024-07-15T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/"},"wordCount":211,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/","name":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2024-07-15T07:36:00+00:00","dateModified":"2024-07-15T07:42:46+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-amolyt-pharma-completes-acquisition-by-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners\u2019 portfolio company Amolyt Pharma completes acquisition by AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/88793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=88793"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/88793\/revisions"}],"predecessor-version":[{"id":88801,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/88793\/revisions\/88801"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=88793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=88793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}